HER2/neu negative salivary duct carcinoma of parotid: A case with forty months recurrence free follow up

This report describes a salivary duct carcinoma (SDC) arising from the extraglandular portion of the Stensen duct. The patient was a 56-year-old man who presented with a palpable, elastic, hard mass without tenderness in the right cheek. Computed tomography revealed a tumor of the extraglandular portion of the Stensen duct. Supraomohyoid right neck dissection and total right parotidectomy were performed, and the histologic diagnosis was SDC of the Stensen duct. Postoperatively, the patient received no additional treatment. Neither recurrence nor metastasis was observed during 4 years of follow-up examination. SDC of the Stensen duct is extremely rare. To our knowledge, there is no report that describes primary SDC arising from that location. We also believe this is the first report that describes the clinical course of primary SDC arising from a Stensen duct.

Download Full-text

Long-Term Recurrence-Free Survival After Salivary Duct Carcinoma of the Parotid: A 10-Year Follow-Up Case Report

Surgical Case Reports ◽

10.31487/j.scr.2020.08.18 ◽

2020 ◽

pp. 1-3

Author(s):

Peer W. Kämmerer ◽

D. Schneider ◽

Peer W. Kämmerer

Keyword(s):

Radiation Therapy ◽

Facial Nerve ◽

Salivary Duct Carcinoma ◽

Adjuvant Radiation ◽

Salivary Duct ◽

Duct Carcinoma ◽

Parotid Region ◽

Parotid Neoplasm ◽

The Right

Salivary duct carcinoma (SDC) represents a very rare and aggressive parotid neoplasm. A 70-year-old male was admitted to the hospital with a swelling of the right parotid region, persisting for twelve weeks. Based on sonography and contrast-enhanced computed tomography, a suspicious lesion showing mass expansion and invasion of surrounding tissues was seen. Intraoperative biopsy brought evidence of SDC. In accordance, surgical treatment included parotidectomy with preservation of the facial nerve as well as ipsilateral neck dissection due to suspicious lymphatic nodes. Afterwards, an adjuvant radiation therapy was undertaken. At 10 years of follow-up, the patient was alive and free of recurrence with full function of the facial nerve. In conclusion, keeping in mind its poor prognosis, the rare parotid salivary duct carcinoma needs aggressive therapy consisting of a surgical as well as a radiation therapy approach.

Download Full-text

Tumor-Infiltrating Lymphocytes and Programmed Death-Ligand 1 Expression in Salivary Duct Carcinoma

American Journal of Clinical Pathology ◽

10.1093/ajcp/aqz113.009 ◽

2019 ◽

Vol 152 (Supplement_1) ◽

pp. S40-S41

Author(s):

Kyriakos Chatzopoulos ◽

Andrea Collins ◽

Joaquin Garcia

Keyword(s):

Tumor Infiltrating Lymphocytes ◽

Salivary Duct Carcinoma ◽

Rank Test ◽

Salivary Duct ◽

Duct Carcinoma ◽

Exact Test ◽

Log Rank Test ◽

Programmed Death ◽

Infiltrating Lymphocytes

Abstract Objectives Salivary duct carcinoma is a rare high-grade salivary gland tumor, sharing common features with invasive ductal carcinoma of the breast—particularly apocrine type. Increased density of tumor-infiltrating lymphocytes (TILs) is a favorable prognostic factor in many solid tumors and has been correlated with elevated expression of programmed death-ligand 1 (PD-L1), a targetable molecule. We investigated the prognostic role of TILs and PD-L1 expression in salivary duct carcinoma. Methods Clinical records and archived surgical pathology material were evaluated from 28 patients with a diagnosis of salivary duct carcinoma at Mayo Clinic Rochester (between 1961 and 2007). TILs were evaluated on hematoxylin and eosin–stained slides and reported as continuous variables. Immunohistochemistry for PD-L1 (clone 22C3) was performed on unstained slides and evaluated using the Combined Positive Score (CPS). Fisher’s exact test was used to assess frequency distribution differences. Log-rank test and Cox proportional hazards model were used to assess the impact of the variables on survival. Results Twenty-eight patients had salivary duct carcinoma (age range 35-87, mean 61), and follow-up averaged 60 months (range 6-252 months). At the end of the follow-up period, 22 patients (79%) had died of salivary duct carcinoma, while remaining patients were alive (4.14%) or had died of other causes (2.7%). For the entire follow-up period, levels of TILs of 40% or more were associated with favorable overall survival (log-rank test, P = .01) and were predictors of better survival in univariate analysis (hazard ratio: 0.18, P = .02). PD-L1 expression was not significantly different between the high and low TIL groups (Fisher’s exact test, P = .67). Survival analysis regarding PD-L1 expression did not yield statistically significant results (log-rank test, P = .74; hazard ratio: 0.87, P = .74). Conclusion High TIL levels, but not PD-L1 expression as determined using the CPS, predict better survival in patients with salivary duct carcinoma.

Download Full-text

Intraductal carcinoma of the minor salivary gland

The Journal of Laryngology & Otology ◽

10.1017/s002221510009397x ◽

1983 ◽

Vol 97 (2) ◽

pp. 189-192 ◽

Cited By ~ 51

Author(s):

Karl T. K. Chen

Keyword(s):

Salivary Gland ◽

Minor Salivary Gland ◽

Salivary Duct Carcinoma ◽

Intraductal Carcinoma ◽

Salivary Duct ◽

Duct Carcinoma

AbstractA case of intraductal carcinoma of the minor salivary gland is reported. It appears to represent the preinvasive phase of infiltrating salivary duct carcinoma. A five-year follow-up showed neither recurrence nor metastasis.

Download Full-text